Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.56 |
| ▸ | CSF1R | P07333 | 11/20 | 0.56 |
| ▸ | FLT3 | P36888 | 5/20 | 0.56 |
| ▸ | KIT | P10721 | 3/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2167309 | 1.00 | KDR (0.56) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL2165049 | 1.00 | KDR (0.56) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL2165042 | 1.00 | KDR (0.56) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL2165037 | 1.00 | KDR (0.56) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL731566 | 0.95 | KDR (0.56) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL731567 | 0.95 | KDR (0.56) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL729164 | 0.89 | KDR (0.65) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL729858 | 0.89 | KDR (0.65) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL731837 | 0.89 | KDR (0.65) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL731787 | 0.87 | KDR (0.64) | KDRCSF1RFLT3KITCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110184013-A1 | Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors | ARRAY BIOPHARMA, INC. | 2011-07-28 | — | — | US | disclosed |
| WO-2010039825-A2 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184013-A1 | Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors | PIM1, PIM2, PIM3 | KDR 37/4885CSF1R 254/4885FLT3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.